<DOC>
	<DOCNO>NCT00521664</DOCNO>
	<brief_summary>The purpose study show therapeutic platelet transfusion strategy ( i.e . platelet transfusion case bleed ) need minimally quarter le transfusion compare standard prophylactic transfusion strategy ( i.e . platelet transfusion without sign bleed platelet count 10.000/ÂµL ) . With experimental transfusion strategy transfusion could safely reduce study hypothesis proven . This first prospective randomize study topic .</brief_summary>
	<brief_title>A Trial Comparing Prophylactic With Therapeutic Platelet Transfusion Strategy Two Groups</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<criteria>AML project inclusion study DSIL OSHO group AML AML M3/M3v include complete remission age 16 80 year write informed consent Autologous project AMl ALL patient first second remission low grade high grade non hodgkin lymphoma morbus hodgkin multiple myeloma conditioning regime : TBI 812 Gy/Cy 120 BEAM BU/CY Melphalan 140200mg/m2 similarly intensive chemotherapy regime age 16 65 year AML project know refractoriness platelet transfusion know major bleed thrombocytopenia reason bleed still ongoing know plasmatic coagulation disorder patient unable give inform consent Autologous project know refractoriness platelet transfusion know major bleed thrombocytopenia reason bleed still ongoing know plasmatic coagulation disorder patient unable give inform consent patient pulmonal cerebral lesion due infection neoplasm patient alamyloidosis</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>proof safety cost effectiveness new therapeutic platelet transfusion strategy</keyword>
</DOC>